Celgene International Sárl (CELG) Release: Results from a Comparative Analysis Shows REVLIMID® Demonstrates Statistically Significant Reduction in Risk of Death and No Evidence of Increased Risk of Progression to AML in Patients with Deletion 5q MDS Compared with Best Supportive Care  
12/12/2011 6:07:15 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) announced results from a retrospective analysis to assess the risk of acute myeloid leukemia (AML) progression and death in REVLIMID (lenalidomide)-treated versus untreated patients with red blood cell (RBC) transfusion-dependent patients with IPSS Low or Int-1 risk myelodysplastic syndromes (MDS) with deletion 5q chromosome (with or without additional cytogenetic abnormalities). These results were presented during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.